Edition:
India

US Department of Defense and Deinove Announce DNV3681 Results


Monday, 20 May 2019 

May 20 (Reuters) - DEINOVE SA ::DNV3681 DEMONSTRATED A SUPERIOR IN VITRO EFFICACY COMPARED TO CIPROFLOXACIN WHICH IS PRODUCT OF REFERENCE WHEN EXPOSED TO BACILLUS ANTHRACIS.DNV3681 IS ACTIVE MOLECULE OF DNV3837, DEVELOPED IN PARALLEL BY DEINOVE AS A POTENTIAL TREATMENT FOR GASTROINTESTINAL INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE.